+1,982.4%
AXTI vs MRNA
+511.3%
+1,471.1%
-73.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.7% | -2.2% | +11.9% | +9.6% |
| 7D | +5.1% | +5.5% | -0.3% | +5.4% |
| 30D | -10.2% | +158.7% | -168.9% | -3.0% |
| 3M | -41.8% | +182.1% | -224.0% | -37.2% |
| 6M | +57.5% | +151.8% | -94.3% | +69.4% |
| YTD | +277.0% | +393.6% | -116.6% | +282.2% |
| 1Y | +1,982.4% | +499.5% | +1,483.0% | +1,932.7% |
| All | +1,982.4% | +511.3% | +1,471.1% | +1,932.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling